Valcke Y J, Rosseel M T, Pauwels R A, Bogaert M G, Van der Straeten M E
Department of Respiratory Diseases, University Hospital, Ghent, Belgium.
Antimicrob Agents Chemother. 1990 Jun;34(6):958-62. doi: 10.1128/AAC.34.6.958.
We studied the penetration of ampicillin-sulbactam in the alveolar lining fluid (ALF) of eight patients after intravenous administration of 2,000 mg of ampicillin and 1,000 mg of sulbactam three times daily over 30 min. Bronchoalveolar lavage was performed on day 3, 30 min after the end of the morning drug administration. The mean penetration ratios (i.e., the ratios of the concentrations in ALF versus those in serum) were 53% (standard error, 12%) and 61% (standard error 31%) for ampicillin and sulbactam, respectively. The concentration ratio of ampicillin versus sulbactam in serum was not significantly different from that in ALF. From a pharmacokinetic point of view, ampicillin-sulbactam is a good choice for treatment of infectious exacerbation of chronic obstructive pulmonary disease and community-acquired bacterial pneumonia, since the concentrations of both drugs in ALF exceed the MICs for the respiratory pathogens responsible.
我们研究了8例患者在静脉输注2000mg氨苄西林和1000mg舒巴坦、每日3次、每次30分钟的情况下,氨苄西林 - 舒巴坦在肺泡衬液(ALF)中的渗透情况。在第3天上午给药结束后30分钟进行支气管肺泡灌洗。氨苄西林和舒巴坦的平均渗透比(即ALF中浓度与血清中浓度之比)分别为53%(标准误,12%)和61%(标准误,31%)。血清中氨苄西林与舒巴坦的浓度比与ALF中的浓度比无显著差异。从药代动力学角度来看,氨苄西林 - 舒巴坦是治疗慢性阻塞性肺疾病感染加重和社区获得性细菌性肺炎的良好选择,因为这两种药物在ALF中的浓度均超过了引起呼吸道感染的病原体的最低抑菌浓度(MIC)。